Company Overview and News

Q1'18 MLP Distribution Recap: Several Growers Overshadowed By 2 Cuts

2018-05-23 seekingalpha
How many MLPs in the AMZ and AMZI grew, maintained, or cut their distributions for 1Q18?

MLPs: Buy After Distribution Cuts Or Run Away?

2018-05-17 seekingalpha
Many income investors sell on cuts to dividends and distributions. Other investors take a vulture-like approach and buy. Who is right?

50 Energy Sector Top Yield And 50 Top Wall St. Target Dividend Stocks For May

2018-05-17 seekingalpha
Energy firms with at least 0.71 broker target upside and 2% dividend yield showed midstream firms high on lists led by Blueknight Energy for upside and Sandridge for yield.

Time to reconvene Capital Markets Taskforce?

It's time to reconvene the Capital Markets Taskforce and have a clear look at whether more state assets can be primed for partial privatisation through the mixed-ownership model (MOM) and beef up liquidity at the NZX.

Stock Investors May Have Missed the Boat on Australia’s Rally - Bloomberg

2018-05-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Ciner Resources: 9% Yield Is Safe, Sell-Off Is Overdone

2018-05-10 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Silver Coast Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »

Is Self-Funding An MLP Pipe Dream?

2018-05-09 seekingalpha
Self-funding has become a buzzword in the MLP space, but is it really translating to MLPs’ capital plans? Admittedly, the shift to self-funding is still in early innings, and the transition will take time. That said, it seems like a logical next step as the MLP space continues to mature. In today’s post, we discuss the impetus behind MLPs’ shift to self-funding and give some examples of MLPs that are pursuing self-funding.

GEL / Genesis Energy, L.P. 10-Q (Quarterly Report)

Document Table of Contents

Genesis Energy, L.P.'s (GEL) CEO Grant Sims on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Welcome to the 2018 First Quarter Conference Call for Genesis Energy. Genesis has four business segments: The Offshore Pipeline Transportation Division is engaged in providing critical infrastructure to move oil produced from the long-lived world-class reservoirs from the Deepwater Gulf of Mexico to Onshore Refining Centers. The Sodium Minerals and Sulfur Services Division includes trona and trona-based exploring, mining, processing, producing, marketing and selling activities, as well as the processing of sour gas streams to remove sulfur and refining operations.

Fran O'Sullivan: Jones' new SOE job spurs unease

There's considerable trepidation brewing within the senior business community on whether Shane Jones' appointment as Associate Minister for State Owned Enterprises signals another round of knuckle-headed Beehive politics.

BRIEF-Genesis Energy Reports Qtrly Net Loss Per Common Unit $0.07

2018-05-04 reuters

NZ shares rise, Z Energy gains after annual earnings

New Zealand shares gained, led by Z Energy following its annual results, with Chorus and Genesis also rising.

NZ shares up as A2 leads index

New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.

Andeavor Logistics downgraded to sector perform from outperform at RBC Capital

2018-05-01 marketwatch
Miller Howard Investments Inc Buys Huntington Bancshares Inc, CenterPoint Energy Inc, Canon Inc, Sells Weyerhaeuser Co, International Paper Co, Cisco Systems Inc

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 371927104